A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...

A brief, four-session stress management program helped ease symptoms of depression and anxiety and reduced stress in people ...

Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...

Chennai: At 25, Bhanupriya was just another TNPSC aspirant from Madurai, preparing for her exams. One day, she lost partial ...

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

A 29-year-old man with multiple sclerosis is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin, the protective brain and spinal cord sheath that is destroyed ...

Dr. Bhargava is an Associate Professor of Neurology at Johns Hopkins University School of Medicine. After obtaining his medical degree from Christian Medical College in Vellore, India, Dr. Bhargava ...

Read more in the PNW Health series. For decades, when someone in Washington state had to manage multiple sclerosis, care quality often depended on where that person lived. Rural Washingtonians ...

Scientists have long suspected that industrial pollutants might help trigger multiple sclerosis, but the latest evidence ...

People who are exposed to certain forever chemicals may be at greater risk of developing multiple sclerosis (MS), according to new research. No one knows why that is, but it could help explain why, ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...